Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Implications of Somatostatin Analogues in the Treatment of Acromegaly.

Literature DB >> 29922369

Implications of Somatostatin Analogues in the Treatment of Acromegaly.

Karim Gariani¹, Patrick Meyer², Jacques Philippe³.

Abstract

Octreotide has an important role in the medical management of acromegaly. Its place in the management of acromegaly as an adjuvant therapy after neurosurgery is well established with a well-demonstrated efficacy. It can also be used in certain clinical conditions as a neoadjuvant treatment. Clinicians and patients should be aware of the possible side effects of octreotide treatment.

Entities: Chemical Disease Species

Keywords: Acromegaly; octreotide; side effects; somatostatin analogues; treatment

Year: 2013 PMID： 29922369 PMCID： PMC6003582 DOI： 10.17925/EE.2013.09.02.132

Source DB: PubMed Journal: Eur Endocrinol ISSN： 1758-3772

55 in total

1. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

Authors: P De; D A Rees; N Davies; R John; J Neal; R G Mills; J Vafidis; J S Davies; M F Scanlon
Journal: J Clin Endocrinol Metab Date: 2003-08 Impact factor: 5.958

2. Consensus statement: medical management of acromegaly.

Authors: S Melmed; F Casanueva; F Cavagnini; P Chanson; L A Frohman; R Gaillard; E Ghigo; K Ho; P Jaquet; D Kleinberg; S Lamberts; E Laws; G Lombardi; M C Sheppard; M Thorner; M L Vance; J A H Wass; A Giustina
Journal: Eur J Endocrinol Date: 2005-12 Impact factor: 6.664

3. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

Authors: Laurence Katznelson; John L D Atkinson; David M Cook; Shereen Z Ezzat; Amir H Hamrahian; Karen K Miller
Journal: Endocr Pract Date: 2011 Jul-Aug Impact factor: 3.443

4. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.

Authors: P Chanson; V Boerlin; C Ajzenberg; Y Bachelot; P Benito; J Bringer; P Caron; B Charbonnel; C Cortet; B Delemer; F Escobar-Jiménez; L Foubert; S Gaztambide; F Jockenhoevel; J M Kuhn; J Leclere; Y Lorcy; L Perlemuter; H Prestele; P Roger; V Rohmer; R Santen; G Sassolas; W A Scherbaum; J Schopohl; E Torres; C Varela; F Villamil; S M Webb
Journal: Clin Endocrinol (Oxf) Date: 2000-11 Impact factor: 3.478

5. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

Authors: A J van der Lely; R K Hutson; P J Trainer; G M Besser; A L Barkan; L Katznelson; A Klibanski; V Herman-Bonert; S Melmed; M L Vance; P U Freda; P M Stewart; K E Friend; D R Clemmons; G Johannsson; S Stavrou; D M Cook; L S Phillips; C J Strasburger; S Hackett; K A Zib; R J Davis; J A Scarlett; M O Thorner
Journal: Lancet Date: 2001-11-24 Impact factor: 79.321

6. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Authors: J Schopohl; C J Strasburger; D Caird; K Badenhoop; F Beuschlein; M Droste; U Plöckinger; S Petersenn
Journal: Exp Clin Endocrinol Diabetes Date: 2010-11-17 Impact factor: 2.949

Review 1. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.

Authors: Busra Aydin; Aysegul Caliskan; Kazim Yalcin Arga
Journal: EPMA J Date: 2021-06-26 Impact factor: 8.836

1 in total

Implications of Somatostatin Analogues in the Treatment of Acromegaly.

1. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission.

2. Consensus statement: medical management of acromegaly.

3. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update.

4. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.

5. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.

6. Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR.

Review 7. Place of cabergoline in acromegaly: a meta-analysis.

Review 8. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.

9. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.

10. Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report.

Review 1. Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.